Clinical Trial Update: A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.

View source ↗

Summary

Pfizer has withdrawn a clinical trial of dacomitnib for non-small cell lung cancer that has spread to the brain.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dacomitnib (dacomitnib)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Non-Small-Cell Lung | Status: WITHDRAWN